Targeting Wnt signaling in myeloma in vivo; Differential effects on tumor burden and myeloma bone disease

Targeting Wnt signaling in myeloma in vivo; Differential effects on tumor burden and myeloma bone disease

Dades bibliogràfiques
Autors principals:	Edwards, C, Edwards, JR, Lwin, S, Mundy, G
Format:	Conference item
Publicat:	2007

Ítems similars

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
per: Edwards, C, et al.
Publicat: (2008)

EphB4 Expression in Osteoblasts is Regulated by Myeloma Cells and the Wnt Signaling Pathway.
per: Bates, A, et al.
Publicat: (2008)

Wnt signaling: bone's defense against myeloma.
per: Edwards, C
Publicat: (2008)

Decreased bone marrow-derived adiponectin contributes to myeloma pathogenesis in vivo
per: Fowler, J, et al.
Publicat: (2010)

Lithium inhibits the development of myeloma bone disease in vivo.
per: Edwards, C, et al.
Publicat: (2006)

The importance of the bone marrow microenvironment in multiple myeloma; Differential responses to lithium in vivo
per: Edwards, C, et al.
Publicat: (2006)

#38. Cholesterol increases bone marrow tumour burden in myeloma in vivo and promotes myeloma cell viability and bortezomib resistance ex vivo
per: B. Gámez, et al.
Publicat: (2024-04-01)

Protein profiling in myeloma in vivo; Effects of bortezomib in a mouse model of myeloma
per: Edwards, C, et al.
Publicat: (2007)

Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.
per: Fowler, J, et al.
Publicat: (2011)

Increasing adiponectin via an apolipoprotein peptide mimetic, L-4F, increases bone formation in normal mice and prevents myeloma bone disease in vivo
per: Fowler, J, et al.
Publicat: (2011)

The pathogenesis of the bone disease of multiple myeloma.
per: Edwards, C, et al.
Publicat: (2008)

Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
per: Fowler, J, et al.
Publicat: (2012)

Host-derived MMP-7 decreases myeloma progression in vivo: An unexpected role for MMP-7 and osteopontin in myeloma pathogenesis
per: Lwin, S, et al.
Publicat: (2011)

Osteoclasts in Myeloma Are Derived from Gr-1(+)CD11b(+) Myeloid Immune Suppressor Cells of the Bone Marrow Niche in Vivo
per: Zhuang, J, et al.
Publicat: (2008)

The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo
per: Gámez, B, et al.
Publicat: (2021)

Host Bone Marrow-Derived Stromal Cells Promote Myeloma Initiation and Development of Osteolysis
per: Fowler, J, et al.
Publicat: (2008)

The ubiquitin-proteasome pathway is dysregulated in myeloma cells in the bone microenvironment in vivo
per: Edwards, C, et al.
Publicat: (2007)

Novel therapeutic targets in myeloma bone disease.
per: Webb, S, et al.
Publicat: (2014)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
per: Lwin, S, et al.
Publicat: (2017)

Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
per: Edwards, C, et al.
Publicat: (2009)

The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo
per: Beatriz Gámez, et al.
Publicat: (2022-01-01)

Tumor-host cell interactions in the bone disease of myeloma.
per: Fowler, J, et al.
Publicat: (2011)

Myeloma cells decrease EphB4 expression in osteoblasts; A novel mechanism for regulation of bone formation in multiple myeloma
per: Bates, A, et al.
Publicat: (2007)

Myeloma cells decrease EphB4 expression in osteoblasts: A novel mechanism for regulation of bone formation in multiple myeloma
per: Bates, A, et al.
Publicat: (2007)

Advances in the management of myeloma bone disease.
per: Shipman, C, et al.
Publicat: (2005)

Diet-induced obesity promotes a myeloma-like condition in vivo.
per: Lwin, S, et al.
Publicat: (2014)

A murine model of myeloma that allows genetic manipulation of the host microenvironment.
per: Fowler, J, et al.
Publicat: (2009)

Osteoclasts in myeloma are derived from Gr-1+CD11b+mononuclear cells of the bone marrow niche
per: Zhuang, J, et al.
Publicat: (2007)

Morphogens and growth factor signalling in the myeloma bone-lining niche
per: Morris, EV, et al.
Publicat: (2021)

Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts.
per: Zhuang, J, et al.
Publicat: (2008)

The Bone Marrow Microenvironment in Multiple Myeloma
per: Edwards, C
Publicat: (2010)

Bone marrow adiposity and multiple myeloma
per: Morris, E, et al.
Publicat: (2018)

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
per: Zhuang, J, et al.
Publicat: (2012)

BTK inhibition in myeloma: targeting the seed and the soil.
per: Edwards, C
Publicat: (2012)

Prospective assessment of myeloma tumour burden and bone disease using DW-MRI and exploratory bone biomarkers
per: Agarwal, G, et al.
Publicat: (2022)

Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential
per: Ingrid Spaan, et al.
Publicat: (2018-05-01)

Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease
per: Gooding, S, et al.
Publicat: (2019)

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
per: Junling Zhuang, et al.
Publicat: (2012-01-01)

Dkk1 modulates osteoclastogenesis and bone resorption: Implications for myeloma bone disease.
per: Oyajobi, B, et al.
Publicat: (2005)

Bone-targeted agents in multiple myeloma
per: Hiroko Nishida
Publicat: (2018-03-01)